In parallel to targeted therapies, immune checkpoint inhibitors (ICIs), anti-CTLA4 antibodies (ipilimumab) and anti-PD1/PDL1 antibodies (pembrolizumab, nivolumab, atezolizumab) have been successfully developed showing tumor regression and long-term durable disease control in melanoma patients [8,9]. Here, CTLA4 is linked to melanoma.